Keywords: Liver, Liver, HCC, VETC, MVI, MRI
Motivation: Microvascular invasion (MVI) and vessels that encapsulate tumor clusters (VETC) are significantly associated with poor prognosis. Sorafenib could improve the prognosis of hepatocellular carcinoma (HCC) patients with either MVI or VETC. Preoperative identification of VM-HCC (VETC+/MVI+, VETC+/MVI-, VETC-/MVI+) is essential for treatment decision-making.
Goal(s): To develop multiregional MRI-based radiomics models and a clinical-radiomics nomogram for predicting VM-HCC, and to explore the prognostic value of these radiomics models.
Approach: Retrospective study.
Results: The peritumor radiomics model and the radiomics-clinical nomogram could effectively identify VM-HCC preoperatively. VM-HCC predicted by the peritumor model was an independent predictor of recurrence-free survival.
Impact: Preoperative non-invasive identification of VM-HCC assists clinicians in developing personalized treatment strategies, thereby improving patient prognosis.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords